Gesellschaftsrecht / M&A

Kapitalmarkt

Steuern

Finanzierungen und Anlageprodukte

IP / IT

Datenschutz

Arbeitsrecht und Vergütung für Führungskräfte

Wettbewerb

Regulierung

Healthcare / Life Sciences

Vectivio

Homburger News

Homburger and VectivBio

On May 22, 2023, VectivBio Holding AG (Nasdaq: VECT), Basel (Switzerland), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare gastrointestinal conditions, and Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced that they had entered into an agreement for Ironwood to launch an all-cash public tender offer to acquire all outstanding shares in VectivBio for USD 17 per share, with an estimated aggregate consideration of approximately USD 1 bn, net of VectivBio cash and debt. The acquisition price represents a premium of 80% relative to the volume-weighted average share price over the previous 90 trading days. The offer is subject to customary conditions and expected to close in mid-2023. VectivBio&#8217;s board of directors unanimously recommends the offer. Orbimed, Forbion and Versant Ventures, and VectivBio&#8217;s directors and officers jointly representing 28.6% of VectivBio&#8217;s shareholdings, entered into tender and support agreements in connection with, and in support of, the offer.
Homburger AG serves as legal and tax advisor to VectivBio on the transaction. The Homburger team includes Andreas Müller, Margrit Marti, Oliver Kneubühl, Francesco Bernasconi, Oliver Dalla Palma, Daniel Wenzinger and Carolina Rodriguez (all Corporate / M&amp;A), Lorenzo Togni (Capital Markets), Stefan Oesterhelt, Philippe Gobet and Kevin Müller (all Tax), Stefan Bindschedler (Financing and Investment Products), Luca Dal Molin (IP / IT; Data Protection), Angela Casey (Employment and Executive Compensation), and Richard Stäuber and Christoph Grüninger (Competition, Regulatory).

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Noema Pharma

On March 7, 2023, Noema Pharma AG announced that it has successfully closed an oversubscribed Series B financing round, raising CHF 103 m (approx. USD 112 m) from new and existing investors. The round was co-led by the European healthcare focused investment firms Forbion and Jeito Capital. UPMC Enterprises and an additional new investor joined existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus to complete the round.
Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The proceeds of the Series B financing will be used to advance Noema Pharma&#8217;s clinical-stage assets.
Homburger AG advises Noema Pharma AG as transaction counsel in this Series B financing round. The Homburger team comprised Andreas Müller, Margrit Marti, Timo Hasler, Thierry Burckhardt, Pepe Hünerwadel and Carolina Rodriguez (all Corporate / M&amp;A; Healthcare / Life Sciences), Luca Dal Molin (IP / IT; Healthcare / Life Sciences) as well as Stefan Oesterhelt and Laetitia Fracheboud (Tax).

Homburger advises Noema Pharma AG on its USD 112 m Series B financing round

On October 15, 2020, VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, announced that it has closed a USD 110 m crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management, with participation from existing investors Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfert Initiative and Cowen Healthcare Investments.
Proceeds from the financing will be used to support the further clinical development of VectivBio&#8217;s lead investigational product, apraglutide, to treat short bowel syndrome (SBS), early commercialization activities and further development of the pipeline through business development initiatives.
The Homburger team was led by partner Andreas Müller and included lead associate Margrit Marti, associates Angela Oppliger and Mirko Stiefel and transaction and corporate support specialist Carolina Rodriguez (all Corporate / M&amp;A), partner Luca Dal Molin and associate Kirsten Schmidt (both IP / IT) as well as partner Stefan Oesterhelt and associates Joël Gyger and Raphaël Fellay (all Tax).

Carolina
Rodríguez

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Homburger advises Noema Pharma AG on its USD 112 m Series B financing round

Homburger advises VectivBio on USD 110 m Crossover Financing

Join the Team

Carolina Rodríguez

Karriere

Sprachen

Teams

CarolinaRodríguez

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Homburger advises Noema Pharma AG on its USD 112 m Series B financing round

Homburger advises VectivBio on USD 110 m Crossover Financing

Join the Team

Carolina Rodríguez

Karriere

Sprachen

Teams

Carolina
Rodríguez